FORT WASHINGTON, Pa., April 16, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical-stage biotechnology company, today announced that Gerard M. McGeehan, Ph.D., Vice President, Discovery Biology, will deliver an oral presentation related to VTP-43742, Vitae's RORγt product candidate for the treatment of autoimmune diseases, at the Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases, which is being held April 19-24 at the Resort at Squaw Creek in Olympic Valley, California.
The presentation details are as follows:
|Title: "The RORγt Blocker, VTP-43742, Suppresses Th17 Activity Providing Greater Benefit than IL-17A Blockade in an EAE Model of Autoimmunity"|
|Date: Thursday, April 23, 2015|
|Time: 2:30 p.m. PT|
|Location: Grand Sierra Ballroom CD|
For more information about the Keystone Symposia on Mechanisms of Pro-Inflammatory Diseases, please visit http://www.keystonesymposia.org/15Z4.
Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs. The company is developing a robust and growing portfolio of novel product candidates generated by Contour®, its proprietary structure-based drug discovery platform.
For additional information, please visit the company's website at www.vitaepharma.com.
CONTACT: INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 email@example.com Westwicke Partners John Woolford (443) 213-0506 firstname.lastname@example.org MEDIA: 6 Degrees PR Tony Plohoros (908) 940-0135 email@example.com